Compare VNRX & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | GBIO |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 35.4M |
| IPO Year | N/A | 2020 |
| Metric | VNRX | GBIO |
|---|---|---|
| Price | $0.30 | $5.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $3.17 | ★ $10.67 |
| AVG Volume (30 Days) | ★ 2.5M | 75.9K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,472,007.00 | ★ $15,270,000.00 |
| Revenue This Year | $324.32 | N/A |
| Revenue Next Year | $247.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.48 | N/A |
| 52 Week Low | $0.29 | $3.00 |
| 52 Week High | $0.94 | $15.30 |
| Indicator | VNRX | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.33 | 40.76 |
| Support Level | $0.29 | $5.14 |
| Resistance Level | $0.33 | $5.38 |
| Average True Range (ATR) | 0.03 | 0.26 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 7.66 | 18.36 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.